- Home
- USIO vs FGEN Comparison
USIO vs FGEN Comparison
Compare USIO & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | FGEN |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.1M | 35.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | USIO | FGEN |
|---|---|---|
| Price | $1.47 | $8.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $146.50 |
| AVG Volume (30 Days) | ★ 46.1K | 26.2K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $83,710,461.00 | $8,298,000.00 |
| Revenue This Year | $5.99 | N/A |
| Revenue Next Year | $11.65 | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $1.24 | $4.85 |
| 52 Week High | $2.92 | $21.94 |
Technical Indicators
Market Signals| Indicator | USIO | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 38.23 |
| Support Level | $1.37 | $7.99 |
| Resistance Level | $1.43 | $9.09 |
| Average True Range (ATR) | 0.05 | 0.37 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 80.00 | 34.82 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.